All In Biotech

Drug Trial Radar · NCT00683800

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

A Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety And Efficacy Of DVS SR For The Treatment Of Vasomotor Symptoms Associated With Menopause

Last checked: Nov 19, 2026Latest source record: Aug 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,186

Actual

Start

Jun 2008

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.

Conditions

  • Vasomotor Symptoms

Interventions

  • desvenlafaxine succinate (DVS) SRDrug

    Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.

  • PlaceboDrug

    Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4Time frame: Baseline and Week 4
  2. Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12Time frame: Baseline and Week 12
  3. Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4Time frame: Baseline and Week 4
  4. Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12Time frame: Baseline and Week 12
  5. Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) EventsTime frame: Baseline up to Month 12

Locations

121 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Mobile, Alabama

  • Pfizer Investigational Site

    Montgomery, Alabama

  • Pfizer Investigational Site

    Glendale, Arizona

  • Pfizer Investigational Site

    Peoria, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Jonesboro, Arkansas

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    Little Rock, Arkansas

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Vista, California

  • Pfizer Investigational Site

    Walnut Creek, California

  • Pfizer Investigational Site

    Colorado Springs, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Englewood, Colorado

  • Pfizer Investigational Site

    Longmont, Colorado

  • Pfizer Investigational Site

    New London, Connecticut

  • Pfizer Investigational Site

    Newark, Delaware

  • Pfizer Investigational Site

    Brooksville, Florida

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Daytona Beach, Florida

  • Pfizer Investigational Site

    Fort Myers, Florida

  • Pfizer Investigational Site

    Gainesville, Florida

  • Pfizer Investigational Site

    Lake Worth, Florida

  • Pfizer Investigational Site

    New Port Richey, Florida

  • Pfizer Investigational Site

    Palm Harbor, Florida

  • Pfizer Investigational Site

    Pembroke Pines, Florida

  • Pfizer Investigational Site

    South Miami, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Decatur, Georgia

  • Pfizer Investigational Site

    Decatur, Georgia

  • Pfizer Investigational Site

    Savannah, Georgia

  • Pfizer Investigational Site

    Boise, Idaho

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.